260 related articles for article (PubMed ID: 26472021)
21. Entrectinib Induces Apoptosis and Inhibits the Epithelial-Mesenchymal Transition in Gastric Cancer with NTRK Overexpression.
Sohn SH; Sul HJ; Kim BJ; Kim HS; Zang DY
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008821
[TBL] [Abstract][Full Text] [Related]
22. Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivo LMNA::NTRK1-rearranged soft-tissue sarcoma cell model.
Chen Y; Steiner S; Hagedorn C; Kollar S; Pliego-Mendieta A; Haberecker M; Plock J; Britschgi C; Planas-Paz L; Pauli C
J Pathol; 2024 Jun; 263(2):257-269. PubMed ID: 38613194
[TBL] [Abstract][Full Text] [Related]
23. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Drilon A; Siena S; Ou SI; Patel M; Ahn MJ; Lee J; Bauer TM; Farago AF; Wheler JJ; Liu SV; Doebele R; Giannetta L; Cerea G; Marrapese G; Schirru M; Amatu A; Bencardino K; Palmeri L; Sartore-Bianchi A; Vanzulli A; Cresta S; Damian S; Duca M; Ardini E; Li G; Christiansen J; Kowalski K; Johnson AD; Patel R; Luo D; Chow-Maneval E; Hornby Z; Multani PS; Shaw AT; De Braud FG
Cancer Discov; 2017 Apr; 7(4):400-409. PubMed ID: 28183697
[TBL] [Abstract][Full Text] [Related]
24. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.
Vaishnavi A; Capelletti M; Le AT; Kako S; Butaney M; Ercan D; Mahale S; Davies KD; Aisner DL; Pilling AB; Berge EM; Kim J; Sasaki H; Park S; Kryukov G; Garraway LA; Hammerman PS; Haas J; Andrews SW; Lipson D; Stephens PJ; Miller VA; Varella-Garcia M; Jänne PA; Doebele RC
Nat Med; 2013 Nov; 19(11):1469-1472. PubMed ID: 24162815
[TBL] [Abstract][Full Text] [Related]
25. Cytoplasmic TrkA Expression as a Screen for Detecting NTRK1 Fusions in Colorectal Cancer.
Choi Y; Won YJ; Lee S; Kim A; Kim Y; Park WY; Jo HJ; Song GA; Kwon CH; Park DY
Transl Oncol; 2018 Jun; 11(3):764-770. PubMed ID: 29689458
[TBL] [Abstract][Full Text] [Related]
26. Identification and characterization of a novel
Milione M; Ardini E; Christiansen J; Valtorta E; Veronese S; Bosotti R; Pellegrinelli A; Testi A; Pietrantonio F; Fucà G; Wei G; Murphy D; Siena S; Isacchi A; De Braud F
Oncotarget; 2017 Aug; 8(33):55353-55360. PubMed ID: 28903424
[TBL] [Abstract][Full Text] [Related]
27. Screening for NTRK-rearranged Tumors Using Immunohistochemistry: Comparison of 2 Different pan-TRK Clones in Melanoma Samples.
Bourhis A; Redoulez G; Quintin-Roué I; Marcorelles P; Uguen A
Appl Immunohistochem Mol Morphol; 2020 Mar; 28(3):194-196. PubMed ID: 30920961
[TBL] [Abstract][Full Text] [Related]
28. Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors.
Rudzinski ER; Lockwood CM; Stohr BA; Vargas SO; Sheridan R; Black JO; Rajaram V; Laetsch TW; Davis JL
Am J Surg Pathol; 2018 Jul; 42(7):927-935. PubMed ID: 29683818
[TBL] [Abstract][Full Text] [Related]
29. NTRK fusion in Japanese colorectal adenocarcinomas.
Yamashiro Y; Kurihara T; Hayashi T; Suehara Y; Yao T; Kato S; Saito T
Sci Rep; 2021 Mar; 11(1):5635. PubMed ID: 33707574
[TBL] [Abstract][Full Text] [Related]
30. A rare case of recurrent ovarian cancer with
Endo Y; Watanabe T; Saito M; Saito K; Suzuki R; Sano H; Natori Y; Sasaki E; Ueda M; Kamo N; Furukawa S; Soeda S; Kono K; Saji S; Fujimori K
Mol Clin Oncol; 2022 Apr; 16(4):90. PubMed ID: 35251641
[No Abstract] [Full Text] [Related]
31. NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer.
Park DY; Choi C; Shin E; Lee JH; Kwon CH; Jo HJ; Kim HR; Kim HS; Oh N; Lee JS; Park OK; Park E; Park J; Shin JY; Kim JI; Seo JS; Park HD; Park J
Oncotarget; 2016 Feb; 7(7):8399-412. PubMed ID: 26716414
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer.
Vaishnavi A; Scherzer MT; Kinsey CG; Parkman GL; Truong A; Ghazi P; Schuman S; Battistone B; Garrido-Laguna I; McMahon M
Cell Rep; 2020 Aug; 32(5):107994. PubMed ID: 32755586
[TBL] [Abstract][Full Text] [Related]
33. TrkA overexpression in non-tumorigenic human breast cell lines confers oncogenic and metastatic properties.
Kyker-Snowman K; Hughes RM; Yankaskas CL; Cravero K; Karthikeyan S; Button B; Waters I; Rosen DM; Dennison L; Hunter N; Donaldson J; Christenson ES; Konstantopoulos K; Hurley PJ; Croessmann S; Park BH
Breast Cancer Res Treat; 2020 Feb; 179(3):631-642. PubMed ID: 31823098
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value and characterization of NTRK1 variation by fluorescence in situ hybridization in esophageal squamous cell carcinoma.
Yu Z; Wang H; Song Q; Huang J; Xu J; Su J; Wang H; Tan L; Wang X; Jiang Z; Chen W; Jiang D; Hou Y
J Cancer Res Clin Oncol; 2021 Oct; 147(10):3113-3121. PubMed ID: 33963905
[TBL] [Abstract][Full Text] [Related]
35. NTRK-rearranged spindle cell neoplasms: a clinicopathological and molecular study of 13 cases with peculiar characteristics at one of the largest institutions in China.
Yin L; Shi C; He X; Qiu Y; Chen H; Chen M; Zhang Z; Chen Y; Zhou Y; Zhang H
Pathology; 2023 Apr; 55(3):362-374. PubMed ID: 36641377
[TBL] [Abstract][Full Text] [Related]
36. Targeting TRK family proteins in cancer.
Khotskaya YB; Holla VR; Farago AF; Mills Shaw KR; Meric-Bernstam F; Hong DS
Pharmacol Ther; 2017 May; 173():58-66. PubMed ID: 28174090
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1-rearranged tumor cells.
Suzuki C; Nishiyama A; Arai S; Tange S; Tajima A; Tanimoto A; Fukuda K; Takumi Y; Kotani H; Takeuchi S; Yanagimura N; Ohtsubo K; Yamamoto N; Omori K; Yano S
Cancer Sci; 2022 Jul; 113(7):2323-2335. PubMed ID: 35363931
[TBL] [Abstract][Full Text] [Related]
38. Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population.
Brzeziańska E; Karbownik M; Migdalska-Sek M; Pastuszak-Lewandoska D; Włoch J; Lewiński A
Mutat Res; 2006 Jul; 599(1-2):26-35. PubMed ID: 16483615
[TBL] [Abstract][Full Text] [Related]
39. [Clinicopathological characteristics of NTRK-rearranged mesenchymal tumors in childhood].
Yin MZ; Ma J; He Q; Shen P; Chen JF; Jin XT; Zhang ZD; Kuick CH; Chen HY; Ng EHQ; Aw SJ; Chang KTE
Zhonghua Bing Li Xue Za Zhi; 2020 Jul; 49(7):675-680. PubMed ID: 32610377
[No Abstract] [Full Text] [Related]
40. Search for NTRK1 proto-oncogene rearrangements in human thyroid tumours originated after therapeutic radiation.
Bounacer A; Schlumberger M; Wicker R; Du-Villard JA; Caillou B; Sarasin A; Suárez HG
Br J Cancer; 2000 Jan; 82(2):308-14. PubMed ID: 10646882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
